Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future
Mark Tyson II, MD, MPH, and Gary D. Steinberg, MD, discuss how NMIBC management has evolved significantly with new FDA approvals including pembrolizumab, nogapendekin alfa, and nadofaragene for BCG-unresponsive disease. Novel therapies in development include sustained-release platforms and immunotherapies.
EP. 1: Standard of Care in NMIBC
January 29th 2025Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant intravesical chemotherapy. High-risk cases receive BCG induction/maintenance therapy after TURBT, with close monitoring.
EP. 2: BCG-Unresponsive NMIBC and Treatments
January 29th 2025Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.
